Is Visepegenatide legal in the United Kingdom?

A published phase 3 in 273 treatment-naive Chinese adults cut glycated haemoglobin 1.36 percentage points against 0.63 on placebo at 24 weeks, and it needs no dose titration. In its phase 1 study 28 percent of healthy volunteers developed antidrug antibodies.

Visepegenatide is exenatide with a polyethylene glycol chain attached, which turns a twice-daily injection into a once-weekly one. It comes from PegBio in Hangzhou and carried the development code PB-119 through most of its published literature.

Mechanism: Exenatide, a synthetic version of exendin-4 from Gila monster venom that acts as a GLP-1 receptor agonist, covalently modified with polyethylene glycol. The PEG chain increases hydrodynamic radius and slows renal clearance, extending half-life from the few hours of native exenatide to around 55 hours, which supports weekly dosing at a fixed dose.

Regulatory history: Not approved in the United States. Reported approved in China in November 2025 after the published phase 3; this site has not resolved a Chinese regulatory document, so treat the approval date as reported rather than as verified here.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Visepegenatide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.